Piramal picks up J&J drugs in strategic move

The Indian company is bulking up on generic injectables to complement its inhalable offerings. 

By Lisa LaMotta • Oct. 12, 2016

Merck inks pay-for-performance deal to boost diabetes drugs

Under an agreement with Aetna, rebates for Januvia and Janumet will be tied to treatment outcomes among type 2 diabetes patients. 

By Ned Pagliarulo • Oct. 11, 2016

Medivir slashes jobs, projects in new cancer focus

The Swedish biotech is in the midst of a major reorganization, with plans to split in two by the end of the year. 

By Suzanne Elvidge • Oct. 11, 2016

Takeda broadens oncology pipeline with Crescendo deal

Under CEO Christophe Weber, Takeda has moved to focus its efforts on development of oncology, gastrointestinal and CNS therapeutics. 

By Ned Pagliarulo • Oct. 10, 2016

Teva sells Actavis generics in UK

The sale is part of a divestiture required as under Teva's acquisition of Allergan’s generic business.

By Joe Cantlupe • Oct. 7, 2016

AstraZeneca conducts fourth sale this week

The big pharma continues to shed non-core assets as it realigns its portfolio to focus on key areas. 

By Lisa LaMotta • Oct. 7, 2016

Pfizer continues trend of shedding non-core assets

The big pharma gets rid of more Hospira assets and gains a stake in pure-play infusion therapy company.

By Suzanne Elvidge • Oct. 7, 2016

Prescribed Reading: Pharma re-focuses, face-off at ESMO, Hep C boxed

Here's a closer look at the clinical trials, M&A, cool science and regulations that are driving the industry this week.

By Lisa LaMotta • Oct. 6, 2016

Catalent out-licenses ADC to Triphase

Triphase Accelerator of San Diego purchased rights to Catalent’s anti-body drug conjugate platform to make clinical headway against lymphoma.

By Joe Cantlupe • Oct. 6, 2016

Celltrion finds new partner after Pfizer exit

The partnership is the latest in a string of biosimilar marketing and production pacts that have popped up in the last few years.

By Jacob Bell • Oct. 6, 2016

BI sells to Elanco to complete Sanofi swap

Eli Lilly, which owns Elanco, will pay $885 million for the portfolio of cat and dog vaccines, adding to its growing animal health business. 

By Suzanne Elvidge • Oct. 6, 2016

OWC Pharma secures funding for cannabinoid drug

Interest in cannabidiol-based drugs has grown, particularly as GW Pharma continues to have success in late-stage clinical trials for Epidiolex. 

By Suzanne Elvidge • Oct. 5, 2016

AstraZeneca: Everything must go!

The British pharma announced its third out-licensing deal in as many days as it continues to shed non-core assets. 

By Lisa LaMotta • Oct. 5, 2016

Daiichi Sankyo links up with AgonOx in latest I/O deal

The Japanese drugmaker has built out its oncology pipeline, but suffered a setback when a Phase 3 lung cancer trial fell short of goal earlier this year. 

By Suzanne Elvidge • Oct. 5, 2016

Celgene CEO: myeloma and glioblastoma both priorities

Following a $600 million buy for Engmab, CEO Mark Alles said the company is expanding beyond multiple myeloma research toward brain cancer. 

By Joe Cantlupe • Oct. 4, 2016

AstraZeneca continues fire sale

The British pharma has been busy selling off non-core assets as part of an overall divestment and refocusing strategy. 

By Lisa LaMotta • Oct. 4, 2016

Amgen inks latest high price-tag research collaboration

With global oncology and neuroscience markets poised for growth, both Amgen and Nuevolution have been active on the deal-making front.

By Jacob Bell • Oct. 4, 2016

Sarepta steps up DMD dealmaking

Less than a week after signing a research deal with Catabasis Pharma, Sarepta paid $40 million upfront for rights to a DMD drug from Summit Therapeutics.

By Ned Pagliarulo • Oct. 4, 2016

AstraZeneca furthers sell-off strategy with new deal

The British pharma out-licensed rights to an inflammatory disease drug to Allergan, receiving $250 million upfront as it narrows its focus on key therapeutic areas. 

By Ned Pagliarulo • Oct. 3, 2016

UPDATED: BI plays hot potato with Hanmi, returns cancer drug

The German drugmaker abruptly abandoned a mid-stage lung cancer drug after reports surfaced about patient deaths. 

By Lisa LaMotta • Sept. 30, 2016

Bluebird flies into TCR deal with Medigene

Medigene will get $15 million upfront to develop TCR candidates, but a long chain of milestones could push total deal value much higher. 

By Suzanne Elvidge • Sept. 30, 2016

Catabasis hopes to ride Sarepta approval wave

Several weeks after winning approval for eteplirsen, the Cambridge-based company is teaming up with another biotech down the street to test a combo therapy in DMD.

By Lisa LaMotta • Sept. 29, 2016

Evotec inks deal with C4X Discovery

The drug discovery companies aim to collaboratively develop drugs targeting cancer and autoimmune diseases.

By Joe Cantlupe • Sept. 29, 2016

Oncodesign snaps up GSK French research center

The British pharma is shedding research facilities as it refocuses resources to key therapeutics areas. 

By Suzanne Elvidge • Sept. 29, 2016

Genentech commits $80M upfront in Hanmi licensing deal

The Roche subsidiary will have sole rights to commercialize Hanmi’s tumor-suppressing drug outside of South Korea.

By Jacob Bell • Sept. 29, 2016